Effect of artificial pancreas systems on glycaemic control in patients with type 1 diabetes: a systematic review and meta-analysis of outpatient randomised controlled trials

The Lancet Diabetes and Endocrinology

Volumn 5, Issue 7, 2017, Pages 501-512

  Weisman, Alanna ^a,b   Bai, Johnny Wei ^a   Cardinez, Marina ^a   Kramer, Caroline K ^a,b   Perkins, Bruce A ^a,b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN;

ALGORITHM; ARTICLE; ARTIFICIAL PANCREAS; BLOOD GLUCOSE METER; BLOOD GLUCOSE MONITORING; CONTINUOUS INFUSION; FUZZY LOGIC; GLUCOSE SENSOR; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; META ANALYSIS; MODEL PREDICTIVE CONTROL ALGORITHM; OUTPATIENT; PRIORITY JOURNAL; PROPORTIONAL INTEGRATIVE DERIVATIVE ALGORITHM; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMOTE SENSING; SYSTEMATIC REVIEW; HYPERGLYCEMIA;

DIABETES MELLITUS, TYPE 1; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIA; PANCREAS, ARTIFICIAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 85019942593     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(17)30167-5     Document Type: Article

References (61)

1. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993), 977–986.
2. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353 (2005), 2643–2653.
3. Fullerton, B, Jeitler, K, Seitz, M, Horvath, K, Berghold, A, Siebenhofer, A, Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus. Cochrane Database Syst Rev, 2, 2014 CD009122.
4. Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 46 (1997), 271–286.
5. Wood, JR, Miller, KM, Maahs, DM, et al. Most youth with type 1 diabetes in the T1D Exchange Clinic Registry do not meet American Diabetes Association or International Society for Pediatric and Adolescent Diabetes clinical guidelines. Diabetes Care 36 (2013), 2035–2037.
6. Bergenstal, RM, Tamborlane, WV, Ahmann, A, et al., for the STAR 3 Study Group. Effectiveness of sensor-augmented insulin-pump therapy in type 1 diabetes. N Engl J Med 363 (2010), 311–320.
7. Miller, KM, Foster, NC, Beck, RW, et al., for the T1D Exchange Clinic Network. Current state of type 1 diabetes treatment in the US: updated data from the T1D Exchange clinic registry. Diabetes Care 38 (2015), 971–978.
8. Kudva, YC, Carter, RE, Cobelli, C, Basu, R, Basu, A, Closed-loop artificial pancreas systems: physiological input to enhance next-generation devices. Diabetes Care 37 (2014), 1184–1190.
9. Hovorka, R, Continuous glucose monitoring and closed-loop systems. Diabet Med 23 (2006), 1–12.
10. Haidar, A, Legault, L, Dallaire, M, et al. Glucose-responsive insulin and glucagon delivery (dual-hormone artificial pancreas) in adults with type 1 diabetes: a randomized crossover controlled trial. CMAJ 185 (2013), 297–305.
11. Hovorka, R, Kumareswaran, K, Harris, J, et al. Overnight closed loop insulin delivery (artificial pancreas) in adults with type 1 diabetes: crossover randomised controlled studies. BMJ, 342, 2011, d1855.
12. Breton, M, Farret, A, Bruttomesso, D, et al. Fully integrated artificial pancreas in type 1 diabetes: modular closed-loop glucose control maintains near normoglycemia. Diabetes 61 (2012), 2230–2237.
13. Dauber, A, Corcia, L, Safer, J, Agus, MS, Einis, S, Steil, GM, Closed-loop insulin therapy improves glycemic control in children aged <7 years: a randomized controlled trial. Diabetes Care 36 (2013), 222–227.
14. Elleri, D, Allen, JM, Kumareswaran, K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 36 (2013), 838–844.
15. Luijf, YM, Hans DeVries, J, Zwinderman, K, et al. Day and night closed-loop control in adults with type 1 diabetes: a comparison of two closed-loop algorithms driving continuous subcutaneous insulin infusion versus patient self-management. Diabetes Care 36 (2013), 3882–3887.
16. Sherr, JL, Cengiz, E, Palerm, CC, et al. Reduced hypoglycemia and increased time in target using closed-loop insulin delivery during nights with or without antecedent afternoon exercise in type 1 diabetes. Diabetes Care 36 (2013), 2909–2914.
17. Capel, I, Rigla, M, Garcia-Saez, G, et al. Artificial pancreas using a personalized rule-based controller achieves overnight normoglycemia in patients with type 1 diabetes. Diabetes Technol Ther 16 (2014), 172–179.
18. Hovorka, R, Allen, JM, Elleri, D, et al. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet 375 (2010), 743–751.
19. Schmidt, S, Boiroux, D, Duun-Henriksen, AK, et al. Model-based closed-loop glucose control in type 1 diabetes: the DiaCon experience. J Diabetes Sci Technol 7 (2013), 1255–1264.
20. Elleri, D, Maltoni, G, Allen, JM, et al. Safety of closed-loop therapy during reduction or omission of meal boluses in adolescents with type 1 diabetes: a randomized clinical trial. Diabetes Obes Metab 16 (2014), 1174–1178.
21. Moher, D, Liberati, A, Tetzlaff, J, Altman, DG, Group, P, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 62 (2009), 1006–1012.
22. Higgins, J, Green, S, (eds.) Cochrane handbook for systematic reviews of interventions, version 5.1.0, March, 2011, The Cochrane Collaboration updated.
23. Russell, SJ, El-Khatib, FH, Sinha, M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 371 (2014), 313–325.
24. Kovatchev, BP, Renard, E, Cobelli, C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 37 (2014), 1789–1796.
25. Elbourne, DR, Altman, DG, Higgins, JP, Curtin, F, Worthington, HV, Vail, A, Meta-analyses involving cross-over trials: methodological issues. Int J Epidemiol 31 (2002), 140–149.
26. Sharifi, A, De Bock, MI, Jayawardene, D, et al. Glycemia, treatment satisfaction, cognition, and sleep quality in adults and adolescents with type 1 diabetes when using a closed-loop system overnight versus sensor-augmented pump with low-glucose suspend function: a randomized crossover study. Diabetes Technol Ther 18 (2016), 772–783.
27. Thabit, H, Tauschmann, M, Allen, JM, et al., for the APCam Consortium and AP@home Consortium. Home use of an artificial beta cell in type 1 diabetes. N Engl J Med 373 (2015), 2129–2140.
28. Haidar, A, Legault, L, Matteau-Pelletier, L, et al. Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 3 (2015), 595–604.
29. Haidar, A, Rabasa-Lhoret, R, Legault, L, et al. Single- and dual-hormone artificial pancreas for overnight glucose control in type 1 diabetes. J Clin Endocrinol Metab 101 (2016), 214–223.
30. Blauw, H, van Bon, AC, Koops, R, DeVries, JH, on behalf of the PCDIAB consortium. Performance and safety of an integrated bihormonal artificial pancreas for fully automated glucose control at home. Diabetes Obes Metab 18 (2016), 671–677.
31. Brown, SA, Kovatchev, BP, Breton, MD, et al. Multinight “bedside” closed-loop control for patients with type 1 diabetes. Diabetes Techn Ther 17 (2015), 203–209.
32. De Bock, MI, Roy, A, Cooper, MN, et al. Feasibility of outpatient 24-hour closed-loop insulin delivery. Diabetes Care 38 (2015), e186–e187.
33. Del Favero, S, Boscari, F, Messori, M, et al. Randomized summer camp crossover trial in 5-to 9-year-old children: outpatient wearable artificial pancreas is feasible and safe. Diabetes Care 39 (2016), 1180–1185.
34. El-Khatib, FH, Balliro, C, Hillard, MA, et al. Home use of a bihormonal bionic pancreas versus insulin pump therapy in adults with type 1 diabetes: a multicentre randomised crossover trial. Lancet 389 (2017), 369–380.
35. Hovorka, R, Elleri, D, Thabit, H, et al. Overnight closed-loop insulin delivery in young people with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 37 (2014), 1204–1211.
36. Kropff, J, Del Favero, S, Place, J, et al., for the AP@home consortium. 2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes Endocrinol 3 (2015), 939–947.
37. Leelarathna, L, Dellweg, S, Mader, JK, et al., on behalf of the AP@home Consortium. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 37 (2014), 1931–1937.
38. Ly, TT, Breton, MD, Keith-Hynes, P, et al. Overnight glucose control with an automated, unified safety system in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Care 37 (2014), 2310–2316.
39. Ly, TT, Roy, A, Grosman, B, et al. Day and night closed-loop control using the integrated Medtronic hybrid closed-loop system in type 1 diabetes at diabetes camp. Diabetes Care 38 (2015), 1205–1211.
40. Ly, TT, Keenan, DB, Roy, A, et al. Automated overnight closed-loop control using a proportional-integral-derivative algorithm with insulin feedback in children and adolescents with type 1 diabetes at diabetes camp. Diabetes Technol Ther 18 (2016), 377–384.
41. Nimri, R, Muller, I, Atlas, E, et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 37 (2014), 3025–3032.
42. Nimri, R, Muller, I, Atlas, E, et al. Night glucose control with MD-Logic artificial pancreas in home setting: a single blind, randomized crossover trial-interim analysis. Pediatr Diabetes 15 (2014), 91–99.
43. Phillip, M, Battelino, T, Atlas, E, et al. Nocturnal glucose control with an artificial pancreas at a diabetes camp. N Engl J Med 368 (2013), 824–833.
44. Russell, SJ, Hillard, MA, Balliro, C, et al. Day and night glycaemic control with a bionic pancreas versus conventional insulin pump therapy in preadolescent children with type 1 diabetes: a randomised crossover trial. Lancet Diabetes Endocrinol 4 (2016), 233–243.
45. Tauschmann, M, Allen, JM, Wilinska, ME, et al. Home use of day-and-night hybrid closed-loop insulin delivery in suboptimally controlled adolescents with type 1 diabetes: a 3-week, free-living, randomized crossover trial. Diabetes Care 39 (2016), 2019–2025.
46. Tauschmann, M, Allen, JM, Wilinska, ME, et al. Day-and-night hybrid closed-loop insulin delivery in adolescents with type 1 diabetes: a free-living, randomized clinical trial. Diabetes Care 39 (2016), 1168–1174.
47. Thabit, H, Lubina-Solomon, A, Stadler, M, et al. Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover study. Lancet Diabetes Endocrinol 2 (2014), 701–709.
48. Bakhtiani, PA, Zhao, LM, El Youssef, J, Castle, JR, Ward, WK, A review of artificial pancreas technologies with an emphasis on bi-hormonal therapy. Diabetes Obes Metab 15 (2013), 1065–1070.
49. Haidar, A, Legault, L, Messier, V, Mitre, TM, Leroux, C, Rabasa-Lhoret, R, Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 3 (2015), 17–26.
50. Pinsker, JE, Lee, JB, Dassau, E, et al. Randomized crossover comparison of personalized MPC and PID control algorithms for the artificial pancreas. Diabetes Care 39 (2016), 1135–1142.
51. Elleri, D, Allen, JM, Kumareswaran, K, et al. Closed-loop basal insulin delivery over 36 hours in adolescents with type 1 diabetes: randomized clinical trial. Diabetes Care 36 (2013), 838–844.
52. Del Favero, S, Bruttomesso, D, Di Palma, F, et al., on behalf of the AP@home Consortium. First use of model predictive control in outpatient wearable artificial pancreas. Diabetes Care 37 (2014), 1212–1215.
53. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med 359 (2008), 1464–1476.
54. Beck, RW, Riddlesworth, T, Ruedy, K, et al., for the DIAMOND Study Group. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. JAMA 317 (2017), 371–378.
55. Anderson, J, Attvall, S, Sternemalm, L, et al. Effect on glycemic control by short- and long-term use of continuous glucose monitoring in clinical practice. J Diabetes Sci Technol 5 (2011), 1472–1479.
56. Battelino, T, Conget, I, Olsen, B, et al. The use and efficacy of continuous glucose monitoring in type 1 diabetes treated with insulin pump therapy: a randomised controlled trial. Diabetologia 55 (2012), 3155–3162.
57. Langendam, M, Luijf, YM, Hooft, L, Devries, JH, Mudde, AH, Scholten, RJ, Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev, 1, 2012 CD008101.
58. Maahs, DM, Buckingham, BA, Castle, JR, et al. Outcome measures for artificial pancreas clinical trials: a consensus report. Diabetes Care 39 (2016), 1175–1179.
59. El-Khatib, FH, Russell, SJ, Magyar, KL, et al. Autonomous and continuous adaptation of a bihormonal bionic pancreas in adults and adolescents with type 1 diabetes. J Clin Endocrinol Metab 99 (2014), 1701–1711.
60. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh Epidemiology of Diabetes Complications experience (1983–2005). Arch Intern Med 169 (2009), 1307–1316.
61. Higgins, JPT, Commentary: heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol 37 (2008), 1158–1160.